Open AccessP413: THE POTENTIAL USE OF AN ORAL HYPOMETHYLATING AGENT, OR‐2100, AS A COMBINATION THERAPY FOR MYELOID MALIGNANCIES
Author(s) -
Kamachi K.,
Ureshino H.,
Kawasoe K.,
YoshidaSakai N.,
Yamamoto Y.,
FukudaKurahashi Y.,
Kurahashi Y.,
Watanabe T.,
Kimura S.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000844540.71364.57
Subject(s) - myeloid leukemia , decitabine , hypomethylating agent , azacitidine , venetoclax , combination therapy , medicine , myeloid , cancer research , hl60 , cancer , leukemia , ven , pharmacology , oncology , dna methylation , chronic lymphocytic leukemia , biology , gene expression , biochemistry , gene , computer security , computer science